natgillin/translations-raw huggingface dataset:
I NSABP B-31- og NCCTG N9831 -studierne blev trastuzumab administreret i kombination med paclitaxel efter AC-kemoterapi.
In the NSABP B-31 and NCCTG N9831 studies, trastuzumab was administered in combination with paclitaxel, following AC chemotherapy.
Symptomerne kan væ re nyreproblemer (svaghed, åndenød, træ thed og forvirring), hjerteproblemer (hjerteflagren eller en hurtigere eller langsommere hjerterytme), krampeanfald, opkast eller diarré, og prikkende fornemmelse i munden, på hæ nderne eller fødderne.
Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart or a faster or slower heartbeat), seizures, vomiting or diarrhoea and tingling in the mouth, hands or feet
Herzuma er et pulver til koncentrat til intravenøs infusionsvæ ske, opløsning, som bliver leveret i et hæ tteglas med en gummiprop, og indeholder 150 mg trastuzumab.
Herzuma is a powder for concentrate for solution for intravenous infusion, which is supplied in a glass vial with a rubber stopper containing 150 mg of trastuzumab.
Efter markedsføringen er der blevet rapporteret tilfæ lde af føtal nyrevæ kstsnedsæ ttelse og/eller nyrefunktionsnedsæ ttelse i forbindelse med oligohydramnion hos gravide kvinder, der får trastuzumab.
In the post-marketing setting, cases of foetal renal growth and/or function impairment in association with oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus, have been reported in pregnant women receiving trastuzumab.
Den mediane samlede overlevelse for den høje HER2-ekspressionsgruppe var 11,8 måneder versus 16 måneder, hazard ratio 0,65 (95 % konfidensinterval 0,51 - 0,83), og den mediane progressionsfri overlevelse var 5,5 måneder versus 7,6 måneder, hazard ratio 0,64 (95 % konfidensinterval 0,51 - 0,79) for henholdsvis FP og FP+H.
The median overall survival for the high HER2 expressing group was 11.8 months versus 16 months, HR 0.65 (95% CI 0.51 - 0.83) and the median progression free survival was 5.5 months versus 7.6 months, HR 0.64 (95% CI 0.51 - 0.79) for FP versus FP + H, respectively.
A: doxorubicin; C: cyclophosphamid; P: paclitaxel; H: trastuzumab * Ved median opfølgningstid, som var 1,8 år for patienterne i AC→P-armen og 2,0 år for patienterne i AC→PH- armen.
A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab * At median duration of follow up of 1.8 years for the patients in the AC→P arm and 2.0 years for patients in the AC→PH arm ** p value for OS did not cross the pre-specified statistical boundary for comparison of AC→PH vs. AC→P
Under behandlingen skal den kardielle vurdering, som udføres ved baseline, gentages hver tredje måned, og efter seponering skal den kardielle vurdering gentages hver sjette måned indtil 24 måneder efter sidste administration af Herzuma.
Cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of Herzuma.
Patienter, som oplever hviledyspnø på grund af komplikationer fra avanceret malignitet og comorbiditet, har muligvis forhøjet risiko for letale infusionsreaktioner.
Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal infusion reaction.
Farmakokinetiske data fra BO15935- og M77004-studierne udført med kvinder med HER2-positiv metastatisk brystkræ ft tydede på, at eksponeringen for paclitaxel og doxorubicin (og hovedmetabolitterne 6-α-hydroxyl-paclitaxel, POH og doxorubicinol, DOL) ikke blev æ ndret ved tilstedevæ relse af trastuzumab (henholdsvis 8 mg/kg eller 4 mg/kg intravenøs støddosis efterfulgt af 6 mg/kg hver 3. uge eller 2 mg/kg intravenøst hver uge).
Pharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC suggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-α hydroxyl-paclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or 4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w intravenous, respectively).
Den anbefalede initiale støddosis er 8 mg/kg legemsvæ gt.
The recommended initial loading dose is 8 mg/kg body weight.
Febril neutropeni, leukopeni, anæ mi, trombocytopeni og neutropeni forekom med hyppigheden ”meget almindelig”.
Febrile neutropenia, leukopenia, anaemia, thrombocytopenia and neutropenia occurred very commonly.
A: doxorubicin; C: cyclophosphamid; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab * På tidspunktet for den endelige analyse af sygdomsfri overlevelse.
A: doxorubicin; C: cyclophosphamide; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab; CI = confidence interval * At the time of the definitive analysis of DFS.
Der blev ikke set nogen gavnlig effekt mht. sygdomsfri overlevelse i denne undergruppe af patienter (hazard ratio = 1,16, 95 % konfidenceinterval [0,73-1,83] for DCarbH (TCH) versus AC→D (AC→T); hazard ratio = 0,97, 95 % konfidenceinterval [0,60-1,55] for AC→DH (AC→TH) versus AC→D).
No disease-free survival (DFS) benefit was noticed in this subgroup of patients (hazard ratio = 1.16, 95% CI [0.73, 1.83] for DCarbH (TCH) versus AC→D (AC→T); hazard ratio = 0.97, 95% CI [0.60, 1.55] for AC→DH (AC→TH) versus AC→D).
Et 20 ml klart type I hæ tteglas med fluroTec-belagt butylgummiprop, som indeholder 150 mg trastuzumab.
A 20 mL clear glass type I vial with fluroTec-coated butyl rubber stopper containing 150 mg of trastuzumab.
Dette kan medføre symptomer som åndenød (herunder åndenød om natten), hoste, væ skeretention (hæ velser) i ben eller arme, og hjertebanken (hjerteflagren eller uregelmæ ssig hjerterytme) (se afsnit 2 ”Kontrol af hjertet”).
This can lead to symptoms such as breathlessness (including breathlessness at night), cough, fluid retention (swelling) in the legs or arms, palpitations (heart fluttering or irregular heart beat) (see 2.
Der er observeret symptomer på kardiel dysfunktion såsom dyspnø, ortopnø, tiltagende hoste, lungeødem, S3-galoprytme eller nedsat ventrikulæ r ejektionsfraktion hos patienter behandlet med trastuzumab (se pkt.
Signs and symptoms of cardiac dysfunction such as dyspnoea, orthopnoea, increased cough, pulmonary oedema, S3 gallop, or reduced ventricular ejection fraction, have been observed in patients treated with trastuzumab (see section 4.4).
Et hæ tteglas indeholder 150 mg trastuzumab, et humaniseret IgG1 monoklonalt antistof, produceret af cellekultursuspension fra pattedyr (ovarie fra kinesisk hamster) og oprenset ved affinitets- og ionbytningskromatografi herunder specifikke virale inaktiverings- og oprensningsprocedurer.
One vial contains 150 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange chromatography including specific viral inactivation and removal procedures.
- BCIRG 006-studiet var designet til at undersøge kombinationen af trastuzumab-behandling med docetaxel efter AC-kemoterapi eller i kombination med docetaxel og carboplatin hos patienter med HER2-positiv tidlig brystkræ ft efter operation.
- The BCIRG 006 study was designed to investigate combining trastuzumab treatment with docetaxel either following AC chemotherapy or in combination with docetaxel and carboplatin in patients with HER2 positive EBC following surgery.
Ugentligt doseringsregime ved metastatisk brystkræ ft
Weekly dosing in metastatic breast cancer
Patienter blev ekskluderet fra de pivotale studier med trastuzumab til adjuverende og neoadjuverende tidlig brystkræ ft, hvis de havde en anamnese med myokardieinfarkt, angina pectoris, der kræ vede medicinsk behandling, tidligere eller eksisterende kongestiv hjerteinsufficiens (NYHA-klasse II-IV), LVEF <55 %, anden kardiomyopati, hjertearytmi, der kræ ver medicinsk behandling, klinisk signifikant hjerteklapsygdom, dårligt kontrolleret hypertension (hvis hypertensionen var kontrolleret på almindelig medicinsk behandling, kunne patienten få præ paratet) og hæ modynamisk effektiv perikardie-effusion.
Patients with history of myocardial infarction (MI), angina pectoris requiring medical treatment, history of or existing CHF (NYHA Class II - IV), LVEF of < 55%, other cardiomyopathy, cardiac arrhythmia requiring medical treatment, clinically significant cardiac valvular disease, poorly controlled hypertension (hypertension controlled by standard medical treatment eligible), and hemodynamic effective pericardial effusion were excluded from adjuvant and neoadjuvant EBC pivotal trials with trastuzumab and therefore treatment cannot be recommended in such patients.
En eksploratorisk subgruppeanalyse udført i ToGA (BO18255) studiet viste, at der ikke var tydelig fordel for den samlede overlevelse ved at tilføje trastuzumab hos patienter med ECOG PS 2 ved baseline [hazard ratio 0,96 (95 % konfidensinterval 0,51 - 1,79)], med ikke målbar sygdom [hazard ratio 1,78 (95 % konfidensinterval 0,87 - 3,66)] eller lokalt fremskreden sygdom [hazard ratio 1,20 (95 % konfidensinterval 0,29 - 4,97)].
In an exploratory subgroup analysis performed in the TOGA (BO18255) trial, there was no apparent benefit on overall survival with the addition of trastuzumab in patients with ECOG PS 2 at baseline [HR 0.96 (95% CI 0.51 - 1.79)], non-measurable [HR 1.78 (95% CI 0.87 - 3.66)] and locally advanced disease [HR 1.20 (95% CI 0.29 - 4.97)].
*Co-primæ re endepunkt for sygdomsfri overlevelse på 1 år versus observation overholdt de præ definerede statistiske græ nser ** Endelig analyse (inkluderende overgang af 52 % af patienterne fra observations-armen til trastuzumab)
*Co-primary endpoint of DFS of 1 year versus observation met the pre-defined statistical boundary **Final analysis (including crossover of 52% of patients from the observation arm to trastuzumab) *** There is a discrepancy in the overall sample size due to a small number of patients who were randomised after the cut-off date for the 12-month median follow-up analysis
Et studie udført på diegivende cynomolgusaber med doser, der er op til 25 gange højere end den humane ugentlige vedligeholdelsesdosis på 2 mg/kg intravenøst formuleret trastuzumab har vist, at trastuzumab udskilles i mæ lken.
A study conducted in lactating Cynomolgus monkeys at doses 25 times that of the weekly human maintenance dose of 2 mg/kg trastuzumab intravenous formulation demonstrated that trastuzumab is secreted in the milk.
Et hæ tteglas indeholder 420 mg trastuzumab, et humaniseret IgG1 monoklonalt antistof, produceret af cellekultursuspension fra pattedyr (ovarie fra kinesisk hamster) og oprenset ved affinitets- og ionbytningskromatografi herunder specifikke virale inaktiverings- og oprensningsprocedurer.
One vial contains 420 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange chromatography including specific viral inactivation and removal procedures.
Median overlevelse (måneder) (95 % konfidensinterval)
Median survival (months) (95% CI)
Sammenligning af trastuzumabs farmakokinetiske data fra studie M77004, hvor kvinder med HER2positiv metastatisk brystkræ ft blev behandlet samtidigt med trastuzumab, paclitaxel og doxorubicin, med trastuzumabs farmakokinetiske data i studier, hvor trastuzumab blev administreret som monoterapi (H0649g) eller i kombination med antracykliner plus cyclophosphamid eller paclitaxel (studie H0648g), tydede på, at doxorubicin og paclitaxel ikke påvirker trastuzumabs farmakokinetik.
Comparison of trastuzumab PK data from Study M77004 in which women with HER2-positive MBC were treated concomitantly with trastuzumab, paclitaxel and doxorubicin to trastuzumab PK data in studies where trastuzumab was administered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide or paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the pharmacokinetics of trastuzumab.
Bivirkningerne præ senteres efter faldende alvorlighed inden for hver hyppighedsgruppering.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
I BCIRG 006-studiet kan hazard ratio for det primæ re endepunkt, sygdomsfri overlevelse, overføres til en absolut gavnlig effekt udtrykt i en 3-års sygdomsfri estimeret overlevelse på 5,8 procentpoint (86,7 % versus 80,9 %) til fordel for AC→DH (trastuzumab)-armen og 4,6 procentpoint (85,5 % versus 80,9 %) til fordel for DCarbH (trastuzumab)-armen sammenlignet med AC→D.
In the BCIRG 006 study for the primary endpoint, DFS, the hazard ratio translates into an absolute benefit, in terms of 3-year disease-free survival rate estimates of 5.8 percentage points (86.7% versus 80.9%) in favour of the AC→DH (trastuzumab) arm and 4.6 percentage points (85.5% versus 80.9%) in favour of the DCarbH (trastuzumab) arm compared to AC→D.
De fleste patienter, som udviklede kongestiv hjerteinsufficiens eller asymptomatisk kardiel dysfunktion i de pivotale studier, opnåede en bedring med standardbehandling af kongestiv hjerteinsufficiens bestående af en ACE-hæ mmer eller angiotensin II receptor-antagonist og en betablokker.
Most patients who developed CHF or asymptomatic cardiac dysfunction in pivotal trials improved with standard CHF treatment consisting of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a beta-blocker.
Den rekonstituerede Herzuma-opløsning indeholder 21 mg/ml trastuzumab.
The reconstituted Herzuma solution contains 21 mg/mL of trastuzumab.
• Doxorubicin 60 mg/m og paclitaxel 150 mg/m administreret hver 3. uge i 3 serier,
 Doxorubicin 60mg/m and paclitaxel 150 mg/m 2, administered 3-weekly for 3 cycles,
I sjældne tilfæ lde er der hos gravide kvinder, der får Herzuma, blevet observeret en nedsat mæ ngde fostervand (den væ ske, der omgiver barnet i livmoderen).
In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has been observed in pregnant women receiving Herzuma.
Hazard ratio kan overføres til en absolut gavnlig effekt udtrykt i en 3-års sygdomsfri estimeret overlevelse på 11,8 procentpoint (87,2 % versus 75,4 %) til fordel for AC→PH (trastuzumab)-armen.
The hazard ratio translates into an absolute benefit, in terms of 3-year disease-free survival rate estimates of 11.8 percentage points (87.2% versus 75.4%) in favour of the AC→PH (trastuzumab) arm.
Sammenligning af farmakokinetiske resultater fra to fase II-studier (BO15935 og M77004) og et fase III-studie (H0648g), hvor patienter blev behandlet med trastuzumab og paclitaxel samtidigt, og 2 fase II-studier, hvor trastuzumab blev administeret som monoterapi (W016229 og MO16982) til kvinder med HER2-positiv metastatisk brystkræ ft, indikerer, at individuel og gennemsnitlig dalvæ rdi af trastuzumab-serumkoncentration varierede inden for og imellem studier.
Comparison of PK results from two Phase II studies (BO15935 and M77004) and one Phase III study (H0648g) in which patients were treated concomitantly with trastuzumab and paclitaxel and two Phase II studies in which trastuzumab was administered as monotherapy (W016229 and MO16982), in women with HER2-positive MBC indicates that individual and mean trastuzumab trough serum concentrations varied within and across studies but there was no clear effect of the concomitant administration of paclitaxel on the pharmacokinetics of trastuzumab.
Hvert hætteglas indeholder 420 mg trastuzumab, som skal opløses i 20 ml vand til injektionsvæ sker.
Each vial contains 420 mg trastuzumab that has to be dissolved in 20 mL of water for injection.
Den anbefalede initiale støddosis af Herzuma er 4 mg/kg legemsvæ gt.
The recommended initial loading dose of Herzuma is 4 mg/kg body weight.
LÆ GEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E)
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
Cmin,ss* (mikrogram/ml)
Cmin,ss* (μg/mL)
Den sygdomsfrie overlevelsesrate blev efter 8 år estimeret til at væ re 77,2 % (95 % konfidensinterval: 75,4-79,1) i AC→PH armen, en absolut gavnlig effekt på 11,8 % sammenlignet med AC→P armen.
At 8 years, the disease-free survival rate was estimated to be 77.2% (95% CI: 75.4, 79.1) in the AC→PH arm, an absolute benefit of 11.8% compared with the AC→P arm.
Data fra et enkelt-arm-studie, JP16003, med trastuzumab (4 mg/kg intravenøs støddosis og 2 mg/kg intravenøst ugentligt) og docetaxel (60 mg/m intravenøst) hos japanske kvinder med HER2-positiv metastisk brystkræ ft, tydede på, at samtidig administration af trastuzumab ikke påvirkede docetaxels enkeltdosis-farmakokinetik.
Data from a single-arm study JP16003 of trastuzumab (4 mg/kg intravenous loading dose and 2 mg/kg intravenous weekly) and docetaxel (60 mg/m intravenous) in Japanese women with HER2-positive MBC, suggested that concomitant administration of trastuzumab had no effect on the single dose pharmacokinetics of docetaxel.
Et 50 ml klart type I hæ tteglas med butylgummiprop, som indeholder 420 mg trastuzumab.
A 50 mL clear glass type I vial with butyl rubber stopper containing 420 mg of trastuzumab.
Herzuma er et pulver til koncentrat til infusionsvæ ske, opløsning, som bliver leveret i et hæ tteglas med en gummiprop, og indeholder 420 mg trastuzumab.
Herzuma is a powder for concentrate for solution for intravenous infusion, which is supplied in a glass vial with a rubber stopper containing 420 mg of trastuzumab.
Resultatet af den opdaterede analyse af sygdomsfri overlevelse (stratificeret hazard ratio = 0,61; 95 % konfidensinterval [0,54-0,69]) viste lignende gavnlig effekt med hensyn til sygdomsfri overlevelse sammenlignet med den endelige primæ re analyse af sygdomsfri overlevelse på trods af, at 24,8 % af patienterne i AC→P armen skiftede til at få trastuzumab.
The updated DFS analysis results (stratified HR = 0.61; 95% CI [0.54, 0.69]) showed a similar DFS benefit compared to the definitive primary DFS analysis, despite 24.8% patients in the AC→P arm who crossed over to receive trastuzumab.
Patienter med metastatisk brystkræ ft eller metastatisk ventrikelkræ ft bør behandles med Herzuma, indtil sygdommen progredierer.
Patients with MBC or MGC should be treated with Herzuma until progression of disease.
Cmax,ss** (mikrogram/ml)
Cmax,ss** (μg/mL)
I denne endelige analyse viste forlæ ngelse af trastuzumab-behandling til en varighed af 2 år ikke yderligere fordel over behandling i 1 år [Sygdomsfri overlevelse hazard ratio i intent-to-treat- (ITT) populaionen 2 år versus 1 år = 0,99 (95 % konfidensinterval: 0,87-1,13), p-væ rdi = 0,90 og samlet overlevelse hazard ratio = 0,98 (0,83-1,15); p-væ rdi = 0,78].
In this final analysis, extending trastuzumab treatment for a duration of two years did not show additional benefit over treatment for 1 year [DFS HR in the intent to treat (ITT) population of 2 years versus 1 year=0.99 (95% CI: 0.87, 1.13), p-value=0.90 and OS HR=0.98 (0.83, 1.15); p-value=0.78].
Hjæ lpestoffer: L-histidinhydrochlorid, L-histidin, polysorbat 20, -trehalosedihydrat.
Excipients: L-histidine hydrochloride, L-histidine, polysorbate 20, α,α-trehalose dihydrate.
Post-hoc eksplorativ analyse med sygdomsfri overlevelse og symptomatiske kardielle hæ ndelser læ ngerevarende opfølgning** hazard ratio 95 % konfidensinterval
Post-hoc exploratory analysis with DFS and symptomatic cardiac events Long term follow-up hazard ratios (95% CI)
Sådan skal du bruge Herzuma
How to use Herzuma
Tidlig brystkræ ft (neoadjuverende-adjuverende behandling)
Early breast cancer (neoadjuvant-adjuvant setting)
Stæ rk skumning under rekonstitutionen eller omrysten af den rekonstituerede opløsning kan medføre problemer med hensyn til den mæ ngde opløsning af Herzuma, der kan træ kkes ud af hæ tteglasset.
Causing excessive foaming during reconstitution or shaking the reconstituted solution may result in problems with the amount of Herzuma that can be withdrawn from the vial.
I et 3 ugers doseringsregime er den anbefalede initiale støddosis af Herzuma 8 mg/kg legemsvæ gt.
As a three-weekly regimen the recommended initial loading dose of Herzuma is 8 mg/kg body weight.
Lineæ r clearance var 0,136 l/dag ved metastatisk brystkræ ft, 0,112 l/dag ved tidlig brystkræ ft og 0,176 l/dag ved fremskreden ventrikelkræ ft.
Linear clearance was 0.136 L/day for MBC, 0.112 L/day for EBC and 0.176 L/day for AGC.
Patienter, som oplever hviledyspnø på grund af komplikationer fra avanceret malignitet og co-morbiditet, har muligvis forhøjet risiko for pulmonale hæ ndelser.
Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of pulmonary events.
- intravenøs 5-fluoruracil - 800 mg/m 2/dag som en kontinuerlig intravenøs-infusion over 5 dage, administreret hver 3. uge i 6 serier (dag 1 til 5 af hver serie)
- intravenous 5-fluorouracil - 800 mg/m 2/day as a continuous intravenous infusion over 5 days, given every 3 weeks for 6 cycles (days 1 to 5 of each cycle)
Hos patienter med tidlig brystkræ ft er der blevet observeret øget hyppighed af symptomatiske og asymptomatiske kardielle hæ ndelser, når trastuzumab blev administreret efter antracyklin-baseret kemoterapi sammenlignet med administration af et ikke-antracyklin-baseret regime med docetaxel og carboplatin.
In patients with EBC an increase in the incidence of symptomatic and asymptomatic cardiac events was observed when trastuzumab was administered after anthracycline-containing chemotherapy compared to administration with a non-anthracycline regimen of docetaxel and carboplatin and was more marked when trastuzumab was administered concurrently with taxanes than when administered sequentially to taxanes.
Den anbefalede ugentlige vedligeholdelsesdosis af Herzuma er 2 mg/kg legemsvæ gt og påbegyndes én uge efter støddosis.
The recommended weekly maintenance dose of Herzuma is 2 mg/kg body weight, beginning one week after the loading dose.
Det Europæ iske Læ gemiddelagentur har dispenseret fra kravet om at fremlæ gge resultaterne af studier med trastuzumab i alle undergrupper af den pæ diatriske population ved bryst- og ventrikelkræ ft (se pkt.
The European Medicines Agency has waived the obligation to submit the results of studies with trastuzumab in all subsets of the paediatric population for breast and gastric cancer (see section 4.2 for information on paediatric use).
ETIKETTERING OG INDLÆ GSSEDDEL
LABELLING AND PACKAGE LEAFLET
De endelige resultater for samlet overlevelse fra den samlede analyse af NSABP B-31- og NCCTG N9831-studierne er opsummeret i tabel 8 nedenfor:
The final OS results from the joint analysis of studies NSABP B-31 and NCCTG N9831 are summarised in Table 8 below:
Behandling med Herzuma må kun påbegyndes af en læ ge med erfaring i administration af cytotoksisk kemoterapi (se pkt.
Herzuma treatment should only be initiated by a physician experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a healthcare professional only.
Cirkulerende shed HER2 ekstracellulæ re domæ ne
Circulating shed HER2 ECD
VIDENSKABELIGE KONKLUSIONER OG BEGRUNDELSER FOR Æ NDRING AF BETINGELSERNE FOR MARKEDSFØ RINGSTILLADELSEN/-TILLADELSERNE
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S)
Andre symptomer som har forbindelse med infusionen er: kvalme, opkastning, smerter, forøget muskelspæ nding og rystelser, hovedpine, svimmelhed, besvæ r med at træ kke vejret, hiven efter vejret, forhøjet eller for lavt blodtryk, forstyrrelser i hjerterytmen (hjertebanken, flakkende hjerte eller uregelmæ ssig hjerterytme), hæ velse i ansigtet og læ berne, udslæ t og træ thedsfølelse.
Other infusion-related symptoms are: feeling sick (nausea), vomiting, pain, increased muscle tension and shaking, headache, dizziness, breathing difficulties, wheezing, high or low blood pressure, heart rhythm disturbances (palpitations, heart fluttering or irregular heart beat), swelling of the face and lips, rash and feeling tired.